Cheryl Gault, Director at Rapport Therapeutics, Inc. (RAPP), bought 9,411 shares at $26.38 ($249K) on 2026-10-22, disclosed to the SEC on 2026-10-22.
Open-market purchase of $249k RAPP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.38 | 8,239 | $217K | 87.3% |
| 2 | $26.92 | 1,172 | $32K | 12.7% |
| Total | $26.45 avg | 9,411 | $249K | 100% |
| Filing → |
| RAPP | SELL | 2026-10-23 | $64K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $974K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |